POLQ Inhibitor Discovery: Targeting DNA Polymerase θ for HTS
Introduction
DNA damage repair (DDR) pathways are essential for maintaining genome stability. When they fail, cancer cells often develop dependencies on backup repair mechanisms—creating therapeutic vulnerabilities. One such pathway, theta-mediated end joining (TMEJ), is orchestrated by DNA polymerase θ (POLQ), a unique enzyme that has become one of the most promising synthetic-lethal targets in oncology.
As PARP inhibitors reach clinical maturity, attention has shifted to POLQ as the next wave of DDR-targeted drug discovery. Inhibiting POLQ has been shown to selectively kill homologous recombination (HR)–deficient tumors, such as those with BRCA1/2 mutations, while sparing healthy cells.
To support this research, BellBrook Labs developed the Enzolution POLQ Helicase Assay System—a high-throughput, homogeneous assay designed to measure the ATPase activity of POLQ’s helicase domain. This system enables direct, quantitative detection of POLQ helicase function, providing an essential tool for inhibitor screening, hit validation, and mechanistic profiling.
What Is POLQ and Why Is It a Drug Target?
A unique dual-domain enzyme
POLQ (DNA polymerase θ) is a multi-domain protein composed of:
- An N-terminal SF2 helicase-like domain, which unwinds DNA and removes RPA and RAD51 from single-stranded overhangs.
- A C-terminal A-family polymerase domain, which fills DNA gaps during repair.
- An intrinsically disordered central region connecting these catalytic cores.
This dual architecture allows POLQ to function as a one-enzyme repair machine, coupling DNA unwinding and synthesis within a single polypeptide.
Role in DNA repair
POLQ drives TMEJ, also called microhomology-mediated end joining (MMEJ), a backup repair pathway that mends double-strand breaks (DSBs) when homologous recombination is compromised.
During TMEJ:
- DNA ends are resected to expose short single-stranded overhangs.
- Microhomologies (2–6 bp) are aligned.
- POLQ displaces protective proteins, anneals the overhangs, and extends the DNA to complete the repair.
Because this process is error-prone, POLQ activity generates small insertions or deletions—creating genomic instability. Yet, for HR-deficient tumors, POLQ-mediated repair is essential for survival.
Learn More About the DNA Damage Response Pathway
POLQ as a synthetic-lethal target
Loss of POLQ in HR-deficient cells leads to catastrophic DSB accumulation and cell death—a hallmark of synthetic lethality. Studies in Nature Communications and The Journal of Clinical Investigation demonstrate that POLQ inhibitors selectively kill BRCA1/2-mutant tumors and enhance sensitivity to PARP inhibition.
Current State of POLQ Inhibitor Discovery
Polymerase-domain inhibitors
The polymerase domain of POLQ has been the focus of initial small-molecule screening efforts. Recent discoveries include allosteric inhibitors that trap POLQ on DNA substrates, showing nanomolar potency and synergy with PARP inhibitors in HR-deficient cancer models.
Learn More About Screening PARP with the Transcreener pADPr PARP Assay
Helicase-domain inhibitors
Emerging research (Nature Communications, 2024) identified a potent helicase inhibitor, AB25583, which binds the ATPase cleft of POLQ-hel with an IC₅₀ of ~6 nM. Structural studies revealed that blocking the helicase domain prevents RAD51 filament displacement—disabling TMEJ repair entirely.
These findings underscore the helicase domain as a druggable site—and one that may be even more selective for cancer cells than polymerase inhibition.
Gaps and opportunities
- Assay bottlenecks: Robust, HTS-compatible assays for helicase inhibition remain limited.
- Domain selectivity: Determining whether helicase or polymerase inhibition drives cytotoxicity.
- Combination therapy: Optimizing POLQ + PARP inhibitor regimens and exploring synergy with immune checkpoint blockade via cGAS–STING activation.
- Safety: Evaluating on-target toxicity, since POLQ contributes to somatic mutagenesis even in normal cells.
Learn More About Screening cGAS with the Transcreener cGAMP cGAS Assay
The Enzolution POLQ Helicase Assay System
BellBrook Labs’ Enzolution POLQ Helicase Assay System provides a ready-to-screen solution for scientists investigating POLQ helicase inhibitors.
Key features
- Direct detection of ATPase activity — measures ATP hydrolysis linked to helicase function.
- Homogeneous, no-wash format — ideal for 384- or 1536-well HTS setups.
- High signal-to-background and Z′ > 0.7 — ensuring statistical robustness.
- Flexible readouts — fluorescence intensity, fluorescence polarization, or TR-FRET.
- Validated with recombinant POLQ-Helicase enzyme — ensuring reproducibility.
Applications
- Primary screening: Identify ATPase inhibitors of POLQ helicase across large compound libraries.
- Mechanistic profiling: Distinguish helicase-domain inhibition from polymerase-domain inhibition.
- Structure–activity relationship (SAR) studies: Support hit-to-lead optimization with quantitative kinetics.
- Combination discovery: Use with PARP inhibitors or DNA-damaging agents to evaluate synergistic cytotoxicity in HR-deficient cell models.
Why it matters
This assay bridges a major gap in POLQ research—providing a reliable, scalable method to evaluate helicase inhibitors in drug discovery pipelines. When paired with cell-based synthetic-lethality assays, it helps teams link biochemical inhibition to phenotypic outcomes.
Recommended Workflow for POLQ Inhibitor Screening
| Stage | Objective | Recommended Tool / Assay |
|---|---|---|
| 1. Biochemical Screening | Identify helicase inhibitors via ATPase activity | Enzolution POLQ Helicase Assay System |
| 2. Orthogonal Confirmation | Validate specificity across other SF2 helicases | Enzolution DDX3 / DHX9 Assay Systems |
| 3. Dose–Response Profiling | Characterize potency and selectivity | Transcreener ADP² ATPase Assay |
| 4. Cell-Based Synthetic-Lethality Test | Compare HR-deficient vs proficient cell lines | DDR-focused cell models |
| 5. Mechanistic / Immunogenicity Studies | Evaluate cGAS–STING activation, micronuclei formation | Collaborate with CRO or academic partner |
By integrating Transcreener and Enzolution technologies, researchers can move seamlessly from primary screening to mechanistic validation—reducing time and assay complexity.
Conclusion
POLQ inhibition represents one of the most promising strategies to exploit DDR dependencies in HR-deficient cancers. As research advances from target validation to clinical translation, the ability to precisely measure POLQ helicase activity becomes crucial.
BellBrook Labs’ Enzolution POLQ Helicase Assay System offers that precision—delivering high-throughput, quantitative data that accelerate discovery. Whether you’re screening chemical libraries, confirming hits, or exploring novel synthetic-lethal combinations, this assay system helps your team screen smarter, not harder.
👉 Learn more about the Enzolution POLQ Helicase Assay System
👉 Request a quote or technical consultation today.
Frequently Asked Questions
What is POLQ and why is it a drug target?
POLQ (DNA polymerase θ) is a dual-domain enzyme that repairs DNA double-strand breaks through theta-mediated end joining (TMEJ). Because HR-deficient cancers rely heavily on this pathway, POLQ inhibition causes synthetic lethality, selectively killing tumor cells.
What role does the helicase domain play in POLQ function?
The helicase domain unwinds DNA and removes proteins such as RPA and RAD51, enabling microhomology pairing during TMEJ. Inhibiting this domain halts POLQ-mediated repair and sensitizes tumors to DNA damage.
How does the Enzolution POLQ Helicase Assay System work?
The assay measures ATP consumption by POLQ helicase using a fluorescence-based detection method that directly measures ADP. It provides a direct, homogeneous readout suitable for high-throughput inhibitor screening.
Which cancers are most likely to respond to POLQ inhibitors?
Cancers harboring BRCA1/2, ATM, or FANCD2 mutations—particularly ovarian, breast, and pancreatic tumors—show strong dependency on POLQ and are prime candidates for synthetic-lethal therapy.
Can POLQ inhibitors enhance immune responses?
Yes. By increasing unrepaired DNA and micronuclei, POLQ inhibition can activate the cGAS–STING pathway, potentially improving response to immune checkpoint inhibitors.
References
-
- Mateos-Gomez, P.-A. et al. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors. Nature Communications 2024; 15:46593. → https://www.nature.com/articles/s41467-024-46593-1
- Zatreanu, D. et al. Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM. Nature Communications 2024; 15:51351. → https://www.nature.com/articles/s41467-024-51351-4
- Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 2015; 518(7538):258-262. → https://www.nature.com/articles/nature14184
- Black, S.J. et al. POLQ suppresses genome instability and alterations in DNA repeat tract lengths. NAR Cancer 2022; 4(3):zcac020. → https://academic.oup.com/narcancer/article/4/3/zcac020/6619444
- Schrempf, A. et al. POLQ: Exploiting a Cancer Vulnerability for Therapy. Trends in Cancer 2020; 6(12):1004-1016. → The PDF: https://www.ideayabio.com/wp-content/uploads/2023/04/Schrempf-A-et-al.-Trends-Cancer-2021.pdf
